The values of the combined detection of serum human epididymis protein E4, CA125 and CA199 in diagnosis of endometrial cancer
10.3969/j.issn.1006-5725.2016.07.022
- VernacularTitle:血清人附睾蛋白E4、CA125、CA199联合诊断子宫内膜癌的价值
- Author:
Zhi ZHANG
;
Hongxia CHEN
;
Xiaoxia XU
- Publication Type:Journal Article
- Keywords:
Endometrial tumor;
Human epididymis protein E4;
CA125;
CA199
- From:
The Journal of Practical Medicine
2016;32(7):1108-1111
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the values of combined detection of serumhuman epididymis protein E4 , CA125 and CA199 in diagnosis of endometrial cancer. Methods 118 patients with endometrial cancer were chosen as group A, 82 patients with benign uterine disease were assigned to group B. Serum levels of HE4, CA125 and CA199 were detected and the positive rates were compared between the two groups. Results Serum levels of HE4, CA125, and CA199, the positive rate were significantly higher in group A than in group B (P <0.05). HE4 positive rate was highest in group A, and group B had no HE4-positive patients. The sensitivity and accuracy of HE4 + CA125 + CA199 were the highest, which was 94.9% and 92.5%. Levels of HE4, CA125 and CA199 and positive rate showed a rising trend as FIGO stage increased (P < 0.05), and HE4 positive rate was significantly higher than those of CA125 and CA199 (P < 0.05). Conclusions HE4 can be used to identify benign and malignant diseases in the uterus , and has a higher diagnostic value of endometrial cancer as compared with CA125 and CA199. Combined detection of HE4, CA125 and CA199 can improve the positive rate and diagnosis accuracy in endometrial cancer.